• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment.

作者信息

Ouyang Yan, Zhao Yafei, Chen Miantang, Li Junru, Zhu Xinyi, Zhao Qing, Ren Hong, Wei Jiali, Chen Nan, Pan Xiaoxia, Xie Jingyuan

机构信息

Department of Nephrology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.

Institute of Nephrology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

出版信息

Kidney Int Rep. 2024 Dec 10;10(3):935-939. doi: 10.1016/j.ekir.2024.12.007. eCollection 2025 Mar.

DOI:10.1016/j.ekir.2024.12.007
PMID:40225385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11993195/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaaf/11993195/808664740443/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaaf/11993195/808664740443/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaaf/11993195/808664740443/gr1.jpg

相似文献

1
A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment.用于治疗严重肾功能损害的IgA肾病患者的布地奈德靶向释放制剂。
Kidney Int Rep. 2024 Dec 10;10(3):935-939. doi: 10.1016/j.ekir.2024.12.007. eCollection 2025 Mar.
2
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.在原发性 IgA 肾病（NefIgArd）患者中，布地奈德靶向释放制剂的疗效和安全性：一项随机 3 期临床试验的 2 年结果。
Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14.
3
Insights on Nefecon, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy.尼福康：布地奈德靶向释放制剂及其在 IgA 肾病患者中的选择性免疫调节作用的新见解。
Drug Des Devel Ther. 2024 Jul 31;18:3415-3428. doi: 10.2147/DDDT.S383138. eCollection 2024.
4
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.多中心、双盲、随机、安慰剂对照的 NefIgArd 试验 A 部分的结果，该试验评估了布地奈德靶向释放制剂治疗原发性免疫球蛋白 A 肾病。
Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19.
5
Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review.目前针对免疫球蛋白 A 肾病中布地奈德靶向释放的认识：全面综述。
Front Immunol. 2023 Jan 4;13:926517. doi: 10.3389/fimmu.2022.926517. eCollection 2022.
6
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.针对 IgA 肾病患者的布地奈德靶向释放与安慰剂的疗效比较（NEFIGAN）：一项双盲、随机、安慰剂对照的 2b 期试验。
Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.
7
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results.耐赋康（Nefecon）在中国内地IgA肾病患者中的疗效与安全性：NefIgArd试验2年结果
Kidney360. 2024 Dec 1;5(12):1881-1892. doi: 10.34067/KID.0000000583. Epub 2024 Oct 9.
8
A Case of Complete Remission of Glucocorticoid-Dependent Nephrotic Syndrome after Targeted-Release Formulation of Budesonide Treatment in a Patient with Mild Mesangial Proliferative IgA Nephropathy.布地奈德靶向释放制剂治疗轻度系膜增生性IgA肾病患者糖皮质激素依赖型肾病综合征完全缓解1例
Nephron. 2025;149(5):283-287. doi: 10.1159/000543271. Epub 2024 Dec 23.
9
New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria.IgA 肾病的新疗法：靶向回肠末端的包肠衣布地奈德可改善蛋白尿。
Nephrol Dial Transplant. 2011 Oct;26(10):3237-42. doi: 10.1093/ndt/gfr052. Epub 2011 Mar 4.
10
A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide.小儿 IgA 肾病受益于靶向释放制剂布地奈德。
Pediatr Nephrol. 2023 Nov;38(11):3849-3852. doi: 10.1007/s00467-023-05968-0. Epub 2023 Apr 11.

引用本文的文献

1
Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide.Gd-IgA1、多聚IgA在靶向释放制剂布地奈德治疗IgA肾病中的预测价值。
Clin Kidney J. 2025 Jul 1;18(7):sfaf203. doi: 10.1093/ckj/sfaf203. eCollection 2025 Jul.

本文引用的文献

1
Exploring Novel Adverse Events of Nefecon.探索耐赋康的新不良事件。
Kidney Int Rep. 2024 Jul 6;9(9):2705-2717. doi: 10.1016/j.ekir.2024.07.006. eCollection 2024 Sep.
2
Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis.口服糖皮质激素联合静脉注射环磷酰胺或单独使用口服糖皮质激素治疗表现为肾病综合征和系膜增生性肾小球肾炎的IgA肾病。
Clin Kidney J. 2023 Jul 13;16(12):2567-2577. doi: 10.1093/ckj/sfad164. eCollection 2023 Dec.
3
IgA nephropathy.
IgA 肾病。
Nat Rev Dis Primers. 2023 Nov 30;9(1):67. doi: 10.1038/s41572-023-00476-9.
4
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.在原发性 IgA 肾病（NefIgArd）患者中，布地奈德靶向释放制剂的疗效和安全性：一项随机 3 期临床试验的 2 年结果。
Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14.
5
Long-Term Outcomes in IgA Nephropathy.IgA 肾病的长期预后。
Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.0000000000000135. Epub 2023 Apr 13.
6
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.多中心、双盲、随机、安慰剂对照的 NefIgArd 试验 A 部分的结果，该试验评估了布地奈德靶向释放制剂治疗原发性免疫球蛋白 A 肾病。
Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19.
7
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.口服甲泼尼龙对 IgA 肾病患者肾功能下降或肾衰竭的影响：TESTING 随机临床试验。
JAMA. 2022 May 17;327(19):1888-1898. doi: 10.1001/jama.2022.5368.
8
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
9
IgA Nephropathy: Core Curriculum 2021.IgA 肾病：2021 年核心课程。
Am J Kidney Dis. 2021 Sep;78(3):429-441. doi: 10.1053/j.ajkd.2021.01.024. Epub 2021 Jul 9.